July 30, 2024
FDA approves Alpha Cognition’s ZUNVEYL for Alzheimer’s treatment
The US Food and Drug Administration (FDA) has approved Alpha Cognition's oral therapy, ZUNVEYL, for the treatment of mild-to-moderate Alzheimer's disease.